Analysis of Related Early Warning Indexes of Cytokine Release Syndrome in Multiple Myeloma Patients after CAR-T Treatment.
10.19746/j.cnki.issn.1009-2137.2021.04.028
- Author:
Chun-Ying YE
1
;
Li-Na ZHAO
1
;
Shi-Yuan WANG
1
;
Hai CHENG
1
;
Wei CHEN
1
;
Kun-Ming QI
1
;
Qing-Yun WU
1
;
Zhen-Yu LI
1
;
Kai-Lin XU
1
;
Jiang CAO
2
Author Information
1. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China.
2. Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, Jiangsu Province, China E-mail: zimu05067@163.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Antigens, CD19;
Cytokine Release Syndrome;
Humans;
Immunotherapy, Adoptive;
Mice;
Multiple Myeloma/therapy*;
Neoplasm Recurrence, Local;
Receptors, Chimeric Antigen
- From:
Journal of Experimental Hematology
2021;29(4):1203-1208
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the relationship between the levels of ferritin, C-reactive protein (CRP), lactate dehydrogenase (LDH) and interleukin-6 (IL-6) in peripheral serum and cytokine release syndrome (CRS) in patients with relapse and/or refractory multiple myeloma (R/R MM) after receiving chimeric antigen receptor T cells (CAR-T) immunotherapy.
METHODS:Twenty-eight patients with R/R MM were treated with 1×10
RESULTS:Among the 28 patients, 27 cases (96.4%) developed CRS, 24 cases (85.7%) in 1-2 grade CRS and 3 cases (10.7%) in 3-5 grade. The severity grade of CRS of 27 patients was positively correlated with the peak values of ferritin, CRP, LDH, and IL-6 in peripheral blood (r
CONCLUSION:After receiving CAR-T cellular immunotherapy, the incidence of CRS in patients with R/R MM is higher, but most of them are in grade 1 or 2. The severity of CRS is positively correlated with the levels of ferritin, CRP, LDH and IL-6 in peripheral blood.
